Infanrix Tetra

Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin, the active ingredient in Infanrix Tetra, is a vaccine presented as a vaccine formulation for intramuscular use. It prevents poliomyelitis type 3 and pertussis in infants and children.

GNH USA supplies Infanrix Tetra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix Tetra is a combination vaccine that targets viral and bacterial agents responsible for serious childhood diseases. - Poliomyelitis (type 3): provides active immunity against poliovirus type 3, reducing the risk of paralytic disease. - Pertussis (whooping cough): induces protective antibodies against pertussis filamentous haemagglutinin, helping prevent infection. - Routine childhood immunisation: administered as part of the standard paediatric schedule to protect against polio and pertussis.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Irritability: increased fussiness in infants. - Loss of appetite: temporary reduction in feeding. - Headache: mild headache reported in some recipients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare febrile convulsions following vaccination. - Encephalopathy: extremely rare inflammation of the brain. - Guillain‑Barré syndrome: very rare autoimmune neuropathy. - Severe allergic reaction: including angioedema or bronchospasm.

Infanrix Tetra should be administered only after careful assessment of the individual's health status. - Screen for severe allergic reactions: avoid if known hypersensitivity to any vaccine component. - Delay vaccination if moderate or severe acute illness is present: postpone until recovery. - Consult healthcare provider for immunocompromised patients: immune response may be diminished. - Observe child for 15 minutes after injection: monitor for immediate hypersensitivity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that affect the immune system. Major Interactions (Avoid): - Live viral vaccines: simultaneous administration may reduce immune response to one or both vaccines. - Immunoglobulins or blood products: can neutralise vaccine antigens and diminish efficacy. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may reduce fever but generally do not affect immunogenicity. - Concurrent inactivated vaccines: generally safe but monitor for increased reactogenicity. - Immunosuppressive therapy: may lower antibody production, requiring serologic follow‑up.